Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences
News Feb 06, 2007
Epitome Biosystems and EMD Biosciences Inc. have announced the successful completion of a collaboration to develop multiplex assays to measure phosphorylation of cell signaling proteins using Epitome’s EpiTag™ technology.
Epitome developed custom antibody and peptide reagents to enable quantitative protein measurements of selected targets for EMD Biosciences. This completes the first commercial partnership for Epitome. Products resulting from this collaboration will be manufactured, marketed and sold for research applications on a world-wide basis by EMD Biosciences Inc. through its Novagen brand.
“Achieving this important product development milestone serves as further validation for our EpiTag™ technology platform and, importantly, will lead to the imminent commercial launch of products,” said Neal Gordon, Ph.D., President, Epitome Biosystems.
“These efforts are contributing to our goal of generating a comprehensive product suite to assess biological function with numerous applications in drug discovery and development,” Gordon said.
“The EpiTag™ technology facilitates the rapid development of robust multiplex immunoassays, including those that can interrogate novel phosphorylated targets” said Graham Scott, Ph.D., Senior Director (Biodiscovery) of EMD Biosciences Inc.
“This joint development project with Epitome has clearly demonstrated the considerable power and utility of this platform technology, and we are excited about commercializing these innovative assays.”
Epitome’s proprietary EpiTag™ technology can enable the development of assays for the quantitative measurement of proteins in “sandwich” assay formats. The flexible technology has been applied to develop antibody array products for broad profiling of intracellular signaling and products for highly quantitative protein measurements in multiplex formats.